Patients with pre-treatment PD-L1+ circulating tumor cells (CTCs) were associated with an inferior prognosis after treatment with PD-(L)1 inhibitors [12–14], in contrast to PD-L1 expression correlating with favorable outcomes in tissue. Here, CD274 is linked to neoplasm.